Compare FedEx Corporation (FDX) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Medpace Holdings Inc — how do they compare? FedEx Corporation trades at $291.71 (market cap $69.04B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: FedEx Corporation is far larger — about 4.1× Medpace Holdings Inc's market cap, and FedEx Corporation pays a 1.67% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and Medpace Holdings Inc for 14 Days on average.
| FDX | MEDP | |
|---|---|---|
Market Cap | $69.04B | $16.82B |
Volume | 1,287,367 | 223,093 |
Sector | Industrials | Health |
52-Week High | $339.35 | $630.19 |
52-Week Low | $180.87 | $393.42 |
Typical Hold Time | 87 Days | 14 Days |
Enterprise Value | $98.68B | $16.44B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $291.73, up 0.93% with a bearish technical signal despite recent earnings beats. The company maintains solid fundamentals with a P/E of 15.73 and net income margin of 4.68%, though revenue has declined from $93.5B in 2022 to $87.9B in 2025. Recent developments include a $300 million electric truck order and strong shareholder support for management.
Wall Street remains bullish with a $307.55 consensus target (57% buy ratings), but rising fuel costs and competitive pressures pose risks. The stock offers value pricing with P/S of 0.74 and positive cash flow projection for 2026, though technical indicators suggest near-term resistance around $294-299.
Medpace (MEDP) trades at $602.70, down slightly by 0.26% on the day, with a neutral technical outlook and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue and net income are projected to grow in 2026, supported by a robust 17.67% net income margin and exceptional ROE of 162.15%. However, valuation ratios like P/E of 35.41 and P/B of 38.77 suggest a premium pricing relative to peers.
The stock offers upside to the consensus price target of $620.44, but risks include high valuation multiples, CEO stock sales, and mixed institutional positioning. Investors should weigh strong profitability against potential overvaluation and monitor Q3 earnings for continued momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
